Insider Buying: Cooper Companies (NASDAQ:COO) EVP Purchases 1,525 Shares of Stock

Key Points

• Cooper Companies EVP Brian Andrews purchased 1,525 shares at an average price of $65.68, increasing his ownership of the company's stock by 7.38% to a total of 22,191 shares.
• The company's stock recently traded down 3.1% to $65.33, with a market capitalization of $12.99 billion and a price-to-earnings ratio of 32.18.
• In its latest earnings report, Cooper Companies reported earnings per share of $1.10, surpassing the consensus estimate of $1.07, with revenues matching analyst expectations at $1.06 billion.

The Cooper Companies, Inc. (NASDAQ:COO - Get Free Report) EVP Brian Andrews acquired 1,525 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average price of $65.68 per share, with a total value of $100,162.00. Following the completion of the transaction, the executive vice president owned 22,191 shares of the company's stock, valued at $1,457,504.88. The trade was a 7.38% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Cooper Companies Trading Down 3.1%

Cooper Companies stock traded down $2.06 during midday trading on Tuesday, hitting $65.33. 3,767,636 shares of the stock were exchanged, compared to its average volume of 2,276,406. The Cooper Companies, Inc. has a fifty-two week low of $61.78 and a fifty-two week high of $112.38. The stock has a market capitalization of $12.99 billion, a price-to-earnings ratio of 32.18, a PEG ratio of 1.63 and a beta of 0.97. The stock's 50-day simple moving average is $72.25 and its 200 day simple moving average is $77.14. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. Cooper Companies's revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Cooper Companies by 1.8% in the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company's stock worth $1,725,963,000 after acquiring an additional 421,423 shares during the last quarter. State Street Corp lifted its stake in Cooper Companies by 1.2% in the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company's stock worth $616,227,000 after acquiring an additional 104,910 shares during the last quarter. Geode Capital Management LLC lifted its stake in Cooper Companies by 2.5% in the second quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company's stock worth $368,893,000 after acquiring an additional 127,907 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Cooper Companies by 3.4% in the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company's stock worth $436,681,000 after acquiring an additional 172,485 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Cooper Companies by 17.0% in the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after acquiring an additional 686,751 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company's stock.

Wall Street Analyst Weigh In

COO has been the subject of several research analyst reports. Morgan Stanley set a $76.00 target price on shares of Cooper Companies and gave the stock an "equal weight" rating in a research note on Thursday, August 28th. Stifel Nicolaus lowered their target price on shares of Cooper Companies from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, August 28th. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $76.00 to $66.00 and set a "neutral" rating for the company in a research note on Thursday, August 28th. Piper Sandler lowered their target price on shares of Cooper Companies from $105.00 to $83.00 and set an "overweight" rating for the company in a research note on Thursday, August 28th. Finally, Mizuho lowered their price objective on shares of Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Cooper Companies presently has a consensus rating of "Moderate Buy" and a consensus target price of $86.64.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.